Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 8

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 8
---
3779810.24/1/2024

73

10.16(a)†License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)10-Q001-3779810.28/6/202010.16(b)†Amendment No. 1 to License and Development Agreement, dated as of October 31, 2023, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)10-K001-3779810.15(b)3/7/202410.17†Patent License Agreement, between Cartesian Therapeutics, Inc. and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute of the National Institutes of Health, dated September 16, 201910-K001-3779810.163/7/202410.18†Patent License Agreement by and between Biogen MA, Inc. and Cartesian Therapeutics, Inc., dated September 8, 202310-K001-3779810.173/7/202410.19#Form of Retention Bonus Letter8-K001-3779810.311/13/202310.20Securities Purchase Agreement, dated as of November 13, 2023, by and among Selecta Biosciences, Inc. and each purchaser identified on Annex A thereto8-K001-3779810.111/13/202310.21Sales Agreement, dated as of December 13, 2024, by and between the Registrant and Leerink Partners LLCS-3333-2838031.212/13/202419.1Cartesian Therapeutics, Inc. Insider Trading Policy———Filed herewith21.1Subsidiaries of Cartesian Therapeutics, Inc.———Filed herewith23.1Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm———Filed herewith31.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002———Filed herewith31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as